核结合因子-急性髓细胞白血病的治疗现状  

Treatment development of core-binding factor-acute myeloid leukemia

作　　者：郑凤美 主鸿鹄[1] Zheng Fengmei;Zhu Honghu(Department of Hematology,Peking University People＇s Hospital,Peking University Institute of Hematology,100044 Beijing,China)

机构地区：[1]北京大学人民医院血液科、北京大学血液病研究所,100044

出　　处：《国际输血及血液学杂志》2018年第3期185-191,共7页International Journal of Blood Transfusion and Hematology

基　　金：国家重点研发计划（2016YFE0202800、2016YFC0902803）;国家自然科学基金（81570128）

摘　　要：核心结合因子-急性髓细胞白血病（CBF-AML）包括伴有t（8；21）（q22；q22）AML与伴有inv（16）（p13q22）／t（16；16）（p13；q22）AML2种类型。CBF-AML患者对大剂量化疗敏感，预后良好。但是，近年来研究发现CBF-AML的预后具有异质性，对其进行危险度分层治疗为目前国际趋势。大剂量阿糖胞苷治疗仍为CBF-AML的首选治疗方案，异基因造血于细胞移植（allo-HSCT）为治疗高危、复发患者的重要手段，靶向药物的出现亦为CBF-AML的治疗提供了新希望。为了指导临床CBF-AML的治疗，笔者拟就CBF-AML的临床治疗研究进展进行介绍。There are two typies of core-binding factor-acute myeloid leukemia （CBF-AML）, including t（8;21）（q22;q22） AML and inv（16）（p13q22）/t（16;16）（p13;q22） AML. Patients with CBF-AML are sensitive to high-dose chemotherapy and have good prognosises. However, recent studies have showed that outcome of CBF-AML is heterogeneous. Risk stratification therapy has become the mainstream at present. High-dose cytarabine is still the first choice for CBF-AML treatment. Moreover, allogeneic hematopoietic stem cell transplantation （allo-HSCT） is an important strategy for high-risk relapse patients. Emergence of targeted drugs also provides new hope for treatment of CBF-AML. This article focuses on the advances in clinical research to provide guide for treatment of CBF-AML.

关 键 词：核结合因子 白血病 髓系 急性 易位 遗传 染色体倒位 造血干细胞移植 

分 类 号：R733.71[医药卫生—肿瘤]